NLRP1 and aging: However, our data suggest that therapeutic intervention with probenecid alone or another agent that inhibits the NLRP1 inflammasome, with corresponding reduction in proinflammatory cytokines, may improve overall cognitive outcomes and reduce symptoms of normal cognitive aging.